KR20050014615A - Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis - Google Patents
Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritisInfo
- Publication number
- KR20050014615A KR20050014615A KR1020030061934A KR20030061934A KR20050014615A KR 20050014615 A KR20050014615 A KR 20050014615A KR 1020030061934 A KR1020030061934 A KR 1020030061934A KR 20030061934 A KR20030061934 A KR 20030061934A KR 20050014615 A KR20050014615 A KR 20050014615A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- arthritis
- treatment
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 206010003246 arthritis Diseases 0.000 title claims abstract description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 239000000401 methanolic extract Substances 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 45
- 240000006079 Schisandra chinensis Species 0.000 claims description 15
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 abstract description 22
- 201000008482 osteoarthritis Diseases 0.000 abstract description 18
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 14
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 14
- 229960002773 hyaluronidase Drugs 0.000 abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 229920002674 hyaluronan Polymers 0.000 abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 9
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract description 6
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 229920002261 Corn starch Polymers 0.000 abstract description 3
- 239000008120 corn starch Substances 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 235000019359 magnesium stearate Nutrition 0.000 abstract description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 239000008101 lactose Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 15
- 230000036541 health Effects 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000005786 degenerative changes Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002038 ethyl acetate fraction Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- -1 pregomoisin Natural products 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- WSSMMNVKLQZMEF-BEKOLJTOSA-N N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O WSSMMNVKLQZMEF-BEKOLJTOSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 229930185889 Epigomisin Natural products 0.000 description 1
- GWDFJIBHVSYXQL-SYTFOFBDSA-N Epigomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GWDFJIBHVSYXQL-SYTFOFBDSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- PLKFSXFJGNZAER-UHFFFAOYSA-N Tigloylgomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(=O)C(C)=CC)C(C)C(C)CC2=CC2=C1OCO2 PLKFSXFJGNZAER-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PLKFSXFJGNZAER-XXDSNBTQSA-N [(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate Chemical compound COc1cc2[C@H](OC(=O)C(\C)=C/C)[C@@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC PLKFSXFJGNZAER-XXDSNBTQSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000011883 total knee arthroplasty Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing and treating arthritis containing Schizandra chinensis extract as an active ingredient.
관절염은 연골 관련 질환의 대표적인 것으로, 류머티스 관절염(rheumatoid arthritis)과 퇴행성 관절염(degenerative arthritis)으로 대별되며, 교통사고나 과도한 운동으로 무릎관절 연골이 손상된 경우도 흔히 발견된다. 현재, 우리나라에서 100만명 정도의 관절염 환자가 있으며, 여성이 남성보다 배이상 많고 그 중에서도 특히 갱년기 여성에게서 많이 볼 수 있는 질환이다.Arthritis is a representative of cartilage-related diseases, which are roughly classified into rheumatoid arthritis and degenerative arthritis, and knee joint cartilage is often found in traffic accidents or excessive exercise. At present, there are about one million arthritis patients in Korea, and women are more than twice as many men, especially menopausal women.
류마티스 관절염은 자가면역 질환의 일종으로, 30~50세의 여성에게 1:4의 비율로 많이 나타나며, 증상은 손가락, 팔꿈치, 무릎 등의 관절이 좌우대칭적으로 염증을 일으켜 부어서 아프고 굳어지며, 특히 새벽에 심하며 몸이 쇠약해지고 미열도 난다. 급성관절류마티스의 관절증세는 몇 일에서 몇 주 이내에 없어지는데 반하여, 류마티스 관절염은 몇 달 몇 년 동안이나 계속되다가, 관절의 변형과 탈구, 근(筋)·건(腱)의 구축(拘縮) 및 강직(强直)을 일으켜 심한 불구가 되기도 한다.Rheumatoid arthritis is a type of autoimmune disease, and it occurs in women of 30 to 50 years at a ratio of 1: 4. Symptoms include symmetrical inflammation of the joints of fingers, elbows, knees, etc. It is severe at dawn, weakness and mild fever. Arthritis of acute joint rheumatism disappears within a few days to weeks, whereas rheumatoid arthritis lasts for months and years, resulting in joint deformation, dislocation, muscle and tendon buildup. And stiffness may cause severe disability.
퇴행성 관절염은 관절 연골이 닳아 없어지면서 국소적인 퇴행성 변화가 나타나는 질환으로서, 골관절염(osteoarthritis) 또는 골관절증 이라고도 한다. 골관절염은 노령화와 밀접한 연관을 갖는 대표적인 퇴행성 질환으로, 전 인구의 10~15% 정도가 앓고 있으며, 특히 65세 이상의 고령인구 중 60~80% 정도가 골관절염을 앓고 있다.Degenerative arthritis is a disease in which local degenerative changes occur as the articular cartilage wears off. Also called osteoarthritis or osteoarthritis. Osteoarthritis is a representative degenerative disease that is closely related to aging. About 10 to 15% of the entire population suffers from osteoarthritis. In particular, about 60 to 80% of the elderly aged 65 or older suffer from osteoarthritis.
퇴행성 관절염의 원인은 노쇠 현상이나 과다한 체중과 관계가 깊으며, 나이가 많아질수록 여성에게서 더 많이 그리고 더 심하게 나타난다. 초기 증상은 한개 또는 두개의 관절이 강직과 함께 쑤시는 듯한 동통이 나타나며, 장기화 되면 관절의 변형 등을 초래하게 된다.The causes of degenerative arthritis are deeply related to senility and excessive weight, and the more and more severely in women as they age. The initial symptom is that one or two joints are swelling with stiffness, and if prolonged, the joints are deformed.
관절연골의 퇴행성 변화의 원인은 아직 규명되어 있지는 않지만, 연골세포 수의 절대적 감소와 연골세포(chondrocytes)에서 일어나는 연골기질 합성과 분해의 불균형이 하나의 원인으로 알려져 있다. 따라서, 관절연골의 퇴행성 변화는 연골기질의 분해로 인하여 연골 강도와 쿠션으로서의 능력이 감소된다.The cause of degenerative changes in articular cartilage has not yet been identified, but an absolute decrease in the number of chondrocytes and imbalances in the synthesis and degradation of chondrocytes in chondrocytes is known as one cause. Thus, degenerative changes in articular cartilage reduce cartilage strength and ability as a cushion due to degradation of cartilage substrate.
현재 임상적으로 사용되고 있는 퇴행성 관절염의 치료는 약물치료제(진통제, 스테로이드제, 비스테로이드계 항염제 등)나 연골보호제(히알루론산, 글루코사민, 콘드로이틴 등)를 이용하거나 수술적 처치(관절경 수술, 경골 근위부 절골술, 관절 부분 치환술, 슬관절 전치환술 등)에 의한다. 그러나 약물치료제의 경우는 통증이나 염증반응 자체를 비특이적으로 완화시키는 효과만을 가지며, 연골보호제는 단지 연골세포에 영양을 공급해 주거나 충격을 완화시킴으로써 관절을 보호해 주는 역할을 할 뿐이다. 또한 스테로이드성 제제는 장기간 복용 시 칼슘의 손실로 골다공증, 고혈압, 당뇨병 등을 초래 할 수 있는 부작용이 있다. 따라서 약물치료는 대부분의 경우 통증을 감소시키는 목적으로만 사용되고 있고, 영구적인 인공관절 치환술이 주를 이루고 있지만 근본적인 치료효과를 주는 약물이나 수술법은 현재까지 없는 실정이다.Currently, clinically used degenerative arthritis can be treated with medications (painkillers, steroids, nonsteroidal anti-inflammatory drugs), cartilage protectors (hyaluronic acid, glucosamine, chondroitin, etc.) or surgical treatment (arthroscopy, proximal tibia). Osteotomy, joint replacement, total knee arthroplasty, etc.). However, drug therapy has only the effect of non-specifically relieving pain or inflammatory response itself, and cartilage protection agent only serves to protect joints by nourishing chondrocytes or alleviating shock. In addition, steroidal drugs have side effects that can lead to osteoporosis, high blood pressure, diabetes, etc. due to loss of calcium when taken for a long time. Therefore, in most cases, the drug is used only for the purpose of reducing pain, and permanent arthroplasty is mainly used, but there are no drugs or surgical methods that provide a fundamental therapeutic effect.
지난 수십년 동안 퇴행성 관절염의 치료를 위해 많은 연구와 노력이 있어 왔지만, 아직 그 병리적 원인이나 근본적인 치료방법은 개발되지 않고 있다.Although much research and efforts have been made for the treatment of degenerative arthritis in the past decades, the pathological cause and the underlying treatment are not yet developed.
최근 들어 한방 치료제 및 영양보조제를 통한 관절염 치료제가 개발되고 있지만 그 치료효과와 작용기전에 관해서는 밝혀져 있지 않다. 따라서 이들 관절염 질환은 기존의 단순 대증요법제인 소염 진통제만으로는 그 질환을 효과적으로 조절하기가 어려울 뿐만 아니라 약물의 장기간 복용에 따른 부작용으로 인하여 현실적으로 환자의 대부분인 노년층에게는 치료에 많은 어려움을 초래하고 있다.Recently, the treatment of arthritis through herbal and nutritional supplements has been developed, but the therapeutic effect and mechanism of action are not known. Therefore, these arthritis diseases are not only difficult to effectively control the disease with the simple anti-inflammatory drugs, the existing simple symptomatic therapy, but also cause a lot of difficulties in the treatment of the elderly, which is the majority of patients in reality due to the side effects of long-term administration of the drug.
따라서, 관절염의 치료를 위해서는 약제를 장기간 복용할 필요가 있기 때문에, 부작용이 적은 약제의 개발이 요구되고 있다.Therefore, in order to treat arthritis, since it is necessary to take a medicament for a long time, development of a medicament with few side effects is desired.
이에 본 발명자들은 생약 추출물 중에서 히알루로니데이즈를 억제하는 물질을 연구하던 중, 오미자 추출물에서 히알루로니데이즈를 억제하는 물질이 있음을 발견하고 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention while searching for a substance for inhibiting hyaluronicides among herbal extracts, and there was a substance for inhibiting hyaluronicase in Schizandra chinensis extract.
본 발명은 오미자 추출물이 히알루로니데이즈를 억제하는 작용이 있는 것을 확인하고, 이를 관절염 예방 및 치료용 의약 또는 식품에 사용하고자 하는 것이다.The present invention confirms that Schisandra chinensis extract has an action of inhibiting hyaluronides, and is intended to be used in medicine or food for preventing and treating arthritis.
도 1은 본 발명의 오미자 추출물의 추출·분리·정제방법을 나타낸 도식도이다.1 is a schematic diagram showing a method for extracting, separating and purifying Schizandra chinensis extract according to the present invention.
도 2는 본 발명의 오미자 추출물이 연골세포 콜라겐 타입 Ⅱ 발현에 미치는 영향을 나타낸 도이다.2 is a diagram showing the effect of Schizandra extract of the present invention on chondrocyte collagen type II expression.
본 발명은 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for the prevention and treatment of arthritis, containing Schizandra chinensis extract as an active ingredient.
또한, 본 발명은 오미자 추출물을 유효성분으로 함유하는 히알루로니데이즈 억제제를 제공한다.The present invention also provides a hyaluronidate inhibitor containing Schizandra chinensis extract as an active ingredient.
이하, 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.
오미자(五味子)의 학명은 Schizandra chinensis Baillon이며 낙엽 활엽 덩굴나무로 잎은 어긋나고 난형(卵形) 또는 도란형(倒卵形)이며 끝은 급히 뾰족하고 톱니가 있으며 뒷면 맥상에 다소 털이 있다. 꽃은 홍백색으로 6~7월에 피며 자웅이주이다. 과실은 식용으로 쓰이고 가지 끝에 이삭모양으로 늘어지며 8~9월에 붉게 익는다. 과실을 오미자(오매자), 북오미자(Schizandrae Fructus)라 한다. 표고200~1,600m 지리산, 전북, 강원도가 주산지이며 충남, 충북을 제외한 전국에 야생하고, 지리적으로 일본, 사할린, 만주, 중국에 분포한다. 과실에는 시잔드롤 (Schizandrol), 시잔드린(Schizandrin) A, B, C, 안질로일고미신(angeloylgomisin) O, P, 에피고미신(epigomisin), 프레고모이신(pregomoisin), 데옥시시잔드린 (Deoxyschizandrin) 등을 함유한다. 오미자는 오래전부터 수렴, 자양, 강장, 진해약, 해주독, 목마름, 수렴고삽, 익기생진, 보신염심 등의 약효를 가져 생약원료로 한방에서 사용해오던 재료이며, 오미자주의 원료로 오래전부터 사용되어 온 것으로서 체내 섭취에 따른 인체 안정성이 이미 확인되어 있다. 오미자 추출물은 중추신경계를 흥분시켜 강장작용과 지력활동과 노동능력을 향상시키며, 당질대사에 영향을 주어 간장 글리코겐의 이화를 촉진하여 글리코겐의 함량 증가작용, 피로회복 촉진작용, 혈압조절작용, 위액분비 조절작용이 있어 저혈압, 동맥경화, 당뇨병, 간염등에 사용되며, 항산화 효과, 항생 해독 기능, 습진 및 피부의 염증을 가라앉히는 기능, 피부노화억제, 항균, 미백 효과가 있어 화장품에도 사용되고 있다.Omija's scientific name is Schizandra chinensis Baillon, a deciduous broad-leaved vine whose leaves are alternate, ovate or obovate, with sharply pointed, jagged, somewhat hairy on the back veins. Flower is reddish white and blooms in June ~ July. Fruits are used for food and hang on the ends of branches. They ripen red in August-September. Fruits are called Schisandra (Fructus) and Schizandrae Fructus. 200 ~ 1,600m above sea level Jirisan, Jeonbuk, and Gangwon-do are the main regions, and are wild in the whole country except Chungnam and Chungbuk, and geographically distributed in Japan, Sakhalin, Manchuria, and China. Fruits include chizandrol, chizandrin A, B, C, angeloylgomisin O, P, epigomisin, pregomoisin, deoxyschizandrin ), And the like. Schisandra chinensis has long been used in herbal medicine as a raw material of medicinal herbs and has long-standing effects such as astringent, nourishment, tonic, ginhae medicine, haejudok, thirsty, astringent shovel, ripe ginjin and bosin salt. As a result, human stability has been confirmed according to the intake of the body. Schisandra chinensis extract stimulates the central nervous system, improves tonic action, intellect and labor capacity, and affects glucose metabolism to promote catabolism of hepatic glycogen, increasing glycogen content, promoting fatigue recovery, controlling blood pressure, and secreting gastric juice. It is used for low blood pressure, arteriosclerosis, diabetes, hepatitis, etc., because it has anti-oxidant effect, antibiotic detoxification function, relieves eczema and inflammation of skin, inhibits skin aging, antibacterial and whitening effect and is also used in cosmetics.
본 발명의 오미자 추출물의 제조방법은 다음과 같다.Preparation method of Schizandra chinensis extract of the present invention is as follows.
오미자를 물 또는 유기용매로 추출한다. 상기 유기용매는 알콜, 클로로포름, 헥산, 에틸아세테이트 중에서 선택하여 사용한다.Schizandra chinensis is extracted with water or organic solvent. The organic solvent is used by selecting from alcohol, chloroform, hexane, ethyl acetate.
추출방법은 상기 용매를 사용하여 냉침, 온침, 가열 등 통상의 추출방법이 가능하다.The extraction method may be a conventional extraction method such as cold needle, warm needle, heating using the solvent.
본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈의 활성을 억제한다.Schizandra chinensis extract of the present invention inhibits the activity of excellent hyaluronides.
히알루론산(hyaluronic acid)은 생체 내 연골조직에 많이 함유되어 있는 물질로, 연골조직의 탄력성을 높이는데 큰 역할을 하며, 수분 함유량이 높고, 뛰어난 점탄성(viscoelasticity)을 지니고 있다.Hyaluronic acid (hyaluronic acid) is a substance that is contained in cartilage tissue in vivo, it plays a big role in increasing the elasticity of the cartilage tissue, has a high moisture content, and has excellent viscoelasticity.
이에 히알루론산의 관절강내 주입이 골관절염으로 인한 통증의 감소 및 치료 효과가 보고되어 임상학적으로도 사용되고 있다.Intraarticular injection of hyaluronic acid has been reported to reduce the pain caused by osteoarthritis and to treat it.
또한, 콜라게나제(collagenase)와 히알루로니데이즈(hyaluronidase) 등이 관절연골세포의 세포사를 증가시키고, 연골세포의 대사작용을 감소시켜 연골조직의 퇴행성 변화를 촉진한다는 연구보고가 있다.In addition, there is a research report that collagenase and hyaluronidase, etc. increase the cell death of articular chondrocytes and decrease the metabolism of chondrocytes, thereby promoting the degenerative changes of chondrocytes.
이와같이 히알루론산의 분해가 골관절염의 유발요인 또는 골관절염의 진행과정을 촉진하는 요인 중의 하나이므로, 히알루론산의 분해효소(히알루로니데이즈) 억제제는 골관절염의 예방 또는 치료제로 사용할 수 있다.Since the decomposition of hyaluronic acid is one of the factors causing osteoarthritis or the process of promoting osteoarthritis, the inhibitor of hyaluronic acid degrading enzyme (hyaluronidase) can be used as a preventive or therapeutic agent for osteoarthritis.
본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈 억제 효과를 나타낸다.Schizandra chinensis extract of the present invention exhibits an excellent hyaluronatease inhibitory effect.
특히, 메탄올 추출물과 에틸아세테이트 추출물이 뛰어난 효과를 나타내었으며, n-헥산 또는 클로로포름 추출물은 히알루로니데이즈 억제 효과가 미약하다.In particular, methanol extract and ethyl acetate extract showed an excellent effect, n-hexane or chloroform extract has a weak effect of inhibiting hyaluronidase.
본 발명에서 히알루로니데이즈에 의해서 분해되어 생성되는 N-아세틸글루코사민(N-acetylglucosamine)을 DMAB(p-dimetylaminobenzaldehyde)를 이용하여 585㎚에서 비색정량 하여 측정한다.In the present invention, N-acetylglucosamine (N-acetylglucosamine) produced by decomposition by hyaluronidase is measured by colorimetric determination at 585 nm using DMAB (p-dimetylaminobenzaldehyde).
상기한 바와같이, 본 발명의 오미자 추출물은 뛰어난 히알루로니데이즈 억제 효과를 나타내는 것을 알 수 있다.As described above, it can be seen that the Schizandra chinensis extract of the present invention exhibits an excellent hyaluronidate inhibitory effect.
본 발명에서 히알루로니데이즈 억제 활성이 연골세포의 세포외기질 합성에 미치는 영향을 알아보기 위해, 연골세포에 히알루로니데이즈를 넣은 것과 연골세포에 히알루로니데이즈 및 오미자 추출물을 함께 처리한 것을 배양한 후 연골세포의 특이적인 세포외기질인 콜라겐 타입 Ⅱ의 발현량을 측정한다.In order to determine the effect of hyaluronidase inhibitory activity on the extracellular matrix synthesis of chondrocytes in the present invention, after incubating the hyaluronidase into chondrocytes and the treatment of hyaluronateides and Schisandra chinensis extract together to the chondrocytes The expression level of collagen type II, a specific extracellular matrix of chondrocytes, is measured.
상기한 바와 같이 본 발명의 오미자 추출물은, 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 억제한다.As described above, the Schizandrae chinensis extract of the present invention inhibits hyaluronides inhibiting the extracellular matrix synthesis of chondrocytes.
본 발명의 조성물은 상기 오미자 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain one or more active ingredients exhibiting the same or similar function in addition to the Schizandra chinensis extract.
본 발명의 조성물은 상기 오미자 추출물에 추가로 다른 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The composition of the present invention may contain at least one active ingredient exhibiting another function in addition to the Schizandra chinensis extract.
본 발명의 조성물은, 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적 또는 식품에서 허용 가능한 담체를 1종 이상 포함할 수 있다. 약제학적 또는 식품에서 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.The composition of the present invention, in addition to the above-described active ingredient for administration may further comprise one or more carriers which are acceptable in pharmaceutical or food. Pharmaceutical or food acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, as necessary. And other conventional additives such as buffers and bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
본 발명의 조성물은 목적하는 방법에 따라 비경구 투여하거나 경구 투여할수 있으며, 경구투여가 바람직하다. 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하나, 일일 투여량은 1~100㎎/㎏의 양을 일회 내지 수회에 나누어 투여하는 것이 바람직하다.The composition of the present invention can be parenterally or orally administered according to the desired method, oral administration is preferred. The dosage varies depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease, but the daily dosage is 1-100 mg / kg once It is preferable to administer dividedly to several times.
본 발명의 조성물은 관절염의 예방 및 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of arthritis.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of preparations for the compositions of the present invention are illustrated below.
제제예 1Formulation Example 1 : 약학적 제제의 제조: Preparation of Pharmaceutical Formulations
1. 산제의 제조1. Preparation of powder
오미자 추출물 에틸아세테이트 분획 2gSchisandra chinensis extract ethyl acetate fraction 2g
유당 1g1g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in airtight cloth to prepare a powder.
2. 정제의 제조2. Preparation of Tablets
오미자 추출물 에틸아세테이트 분획 100㎎Schizandra chinensis extract ethyl acetate fraction 100mg
옥수수전분 100㎎Corn Starch 100mg
유 당 100㎎Lactose 100mg
스테아린산 마그네슘 2㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of Capsule
오미자 추출물 에틸아세테이트 분획 100㎎Schizandra chinensis extract ethyl acetate fraction 100mg
옥수수전분 100㎎Corn Starch 100mg
유 당 100㎎Lactose 100mg
스테아린산 마그네슘 2㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
본 발명의 조성물은 관절염에 기인하는 질환의 개선을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때 첨가하는 양은 건강식품 조성물일 경우 전체 식품 중량의 1~5 중량%, 바람직하게는 3 중량%로 가할 수 있으며, 건강음료 조성물일 경우 100㎖를 기준으로 1~3g, 바람직하게는 2g의 비율로 가할 수 있다.The compositions of the present invention may be added to foods or beverages for the purpose of ameliorating diseases caused by arthritis. In this case, the amount added may be added in an amount of 1 to 5% by weight, preferably 3% by weight of the total food weight in the case of the health food composition, and in the case of the health beverage composition, 1 to 3g, preferably 2g Can be added in proportion.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나,사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 2~5g, 바람직하게는 약 4g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as tautin and stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 2-5 g, preferably about 4 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 1~5 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid. Carbonating agents and the like used in beverages. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 1 to 5 parts by weight per 100 parts by weight of the composition of the present invention.
제제예 2Formulation Example 2 : 식품의 제조: Manufacture of food
본 발명의 오미자 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the Schisandra chinensis extract of the present invention were prepared as follows.
1. 조리용 양념의 제조1. Preparation of Cooking Seasonings
본 발명의 오미자 추출물 20 ~ 95 중량%로 건강 증진용 조리용 양념을 제조하였다.Schisandra chinensis extract of the present invention was prepared in 20 to 95% by weight for health promotion cooking seasoning.
2. 토마토 케찹 및 소스의 제조2. Preparation of Tomato Ketchup and Sauce
본 발명의 오미자 추출물 0.2 ~ 1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2 ~ 1.0% by weight of Schizandra extract of the present invention was added to tomato ketchup or sauce to prepare tomato ketchup or sauce for health promotion.
3. 밀가루 식품의 제조3. Manufacturing of Flour Foods
본 발명의 오미자 추출물 0.5 ~ 5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5 ~ 5.0% by weight of Schizandra chinensis extract of the present invention was added to the flour, and using the mixture to prepare bread, cakes, cookies, crackers and noodles to prepare foods for health promotion.
4. 스프 및 육즙(gravies)의 제조4. Preparation of soups and gravy
본 발명의 오미자 추출물 0.1 ~ 5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1-5.0 wt% of Schizandra chinensis extract of the present invention was added to soups and broths to prepare meat products for health promotion, soups and noodles for noodles.
5. 그라운드 비프(ground beef)의 제조5. Preparation of Ground Beef
본 발명의 오미자 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10 wt% of Schisandra chinensis extract of the present invention was added to ground beef to prepare a ground beef for health promotion.
6. 유제품(dairy products)의 제조6. Manufacture of Dairy Products
본 발명의 오미자 추출물 5 ~ 10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5 to 10% by weight of Schizandra chinensis extract of the present invention was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.
7. 선식의 제조7. Manufacture of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh using a grinder.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
본 발명의 오미자 추출물을 진공 농축기에서 감압·농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60메쉬로 분쇄하여 건조분말을 얻었다.The Schizandra chinensis extract of the present invention was decompressed and concentrated in a vacuum concentrator, and the dried product obtained by drying with a sprayer or a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 오미자 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.It was prepared by combining the dry powder of the grains, seeds and Schisandra chinensis extract prepared in the following ratio.
곡물류(현미 30중량%, 율무 15중량%, 보리 20중량%),Cereals (30% by weight brown rice, 15% by weight radish, 20% by weight barley),
종실류(들깨 7중량%, 검정콩 8중량%, 검정깨 7중량%),Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame),
오미자 추출물의 건조분말(3 중량%),Dry powder of Schizandra chinensis extract (3% by weight),
영지(0.5중량%),Ganoderma lucidum (0.5% by weight),
지황(0.5중량%)Foxglove (0.5 wt%)
제제예 3Formulation Example 3 : 음료의 제조: Preparation of Beverages
1. 탄산음료의 제조1. Preparation of Carbonated Drinks
설탕 5~10%, 구연산 0.05~0.3%, 카라멜 0.005~0.02%, 비타민 C 0.1~1%의 첨가물을 혼합하고, 여기에 79~94%의 정제수를 섞어서 시럽을 만들고, 상기 시럽을 85~98℃에서 20~180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를0.5~0.82%를 주입하여 본 발명의 오미자 추출물을 함유하는 탄산음료를 제조하였다.5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% of vitamin C are mixed, and 79-94% purified water is mixed to make syrup, and the syrup is 85-98 Sterilizing at 20 ℃ for 180 seconds to mix with a cooling water 1: 1: ratio of carbon dioxide gas was injected 0.5 ~ 0.82% to prepare a carbonated beverage containing Schizandra extract of the present invention.
2. 건강음료의 제조2. Manufacture of health drinks
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 오미자 추출물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization by homogeneously mixing minor ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and Schizandra chinensis extract Health drinks were prepared by packaging in small packaging containers such as plastic bottles.
3. 야채쥬스의 제조3. Preparation of Vegetable Juice
본 발명의 오미자 추출물 5g을 토마토 또는 당근 쥬스 1,000㎖에 가하여 건강 증진용 야채쥬스를 제조하였다.5 g of Schisandra chinensis extract of the present invention was added to 1,000 ml of tomato or carrot juice to prepare a vegetable juice for health promotion.
4. 과일쥬스의 제조4. Preparation of Fruit Juice
본 발명의 오미자 추출물 1g을 사과 또는 포도 쥬스 1,000㎖에 가하여 건강 증진용 과일쥬스를 제조하였다.1 g of Schizandra chinensis extract of the present invention was added to 1,000 ml of apple or grape juice to prepare fruit juice for health promotion.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.
실시예 1Example 1 : 오미자 추출물의 제조: Preparation of Schizandra chinensis Extract
1. 오미자 조추출물1.Schisandra chinensis extract
1) 오미자 물 추출물1) Schizandra Water Extract
건조한 오미자 열매 3㎏을 세절 한 후, 물로 24시간씩 5회 반복하여 교반 추출한 다음 여과지에 여과한 후 여액을 감압농축하여 물 추출물을 얻었다.After cutting 3 kg of dried Schisandra chinensis fruits, stirring and extracting was repeated five times for 24 hours each with water, and then filtered through a filter paper, and the filtrate was concentrated under reduced pressure to obtain a water extract.
2) 오미자 유기용매 추출물2) Schizandra Organic Solvent Extract
건조한 오미자 열매 3㎏을 세절 한 후, 메탄올로 24시간씩 5회 반복하여 교반 추출한 다음 여과지에 여과한 후 여액을 감압농축하여 메탄올 추출물을 얻었다.After cutting 3 kg of dried Schisandra chinensis fruit, the mixture was extracted by stirring repeatedly for 5 hours with methanol for 24 hours, filtered through a filter paper, and the filtrate was concentrated under reduced pressure to obtain a methanol extract.
2. 오미자 추출물의 분리2. Isolation of Schizandra chinensis Extract
상기 1의 2)에서 얻어진 메탄올 추출물에 증류수를 넣은 후 헥산으로 추출하고, 그 추출잔사를 클로로포름으로 재추출 한 후, 그 추출잔사를 다시 에틸아세테이트로 추출하였다.Distilled water was added to the methanol extract obtained in 2) and extracted with hexane. The extracted residue was reextracted with chloroform, and the extracted residue was extracted with ethyl acetate again.
상기 에틸아세테이트 추출물을 TLC(Thin Layer Chromatography)를 이용하여 활성물질의 수를 확인하고, 실리카(silica), C18및 NH2크로마토그래피 컬럼을 이용하여 활성분획을 정제하였다.The ethyl acetate extract was checked for the number of active substances using TLC (Thin Layer Chromatography), and the active fractions were purified using silica, C 18 and NH 2 chromatography columns.
본 발명의 오미자 추출물의 추출·분리·정제방법은 도 1에 나타내었다.Extraction, separation and purification of the Schizandra chinensis extract of the present invention is shown in FIG.
실험예 1Experimental Example 1 : 오미자 추출물의 히알루로니데이즈 활성 억제도 측정: Determination of Hyaluronidase Activity of Schizandra chinensis Extract
본 발명의 오미자 추출물의 히알루로니데이즈의 활성 억제도를 알아보기 위하여 Morgan-Elson Assay 법을 이용하여 활성을 측정하였다.In order to determine the inhibitory activity of hyaluronides of the Schizandra chinensis extract of the present invention, the activity was measured using the Morgan-Elson Assay method.
인산완충용액에 녹인 히알루론산과 DMSO에 녹인 오미자 추출물을 각각 넣고 37℃에서 20분간 배양하였다. 배양한 후에 화합물 48/80용액을 넣고 2차 배양하였다. 히알루론산을 넣고 3차 배양 한 후 K3BO3를 넣고 열탕에서 가열하여 반응을 중지시켰다. 원심분리 후, 히알루론산이 히알루로니데이즈에 의해서 분해되어 생성되는 N-알세틸글루코사민(N-acetylglucosamine)을 DMAB(p-dimetylaminobenzaldehyde)를 이용하여 585㎚에서 비색정량 하여 활성을 검증하였다.Hyaluronic acid dissolved in phosphate buffer solution and Schizandra chinensis extract dissolved in DMSO, respectively, were added and incubated at 37 ° C. for 20 minutes. After incubation, the compound 48/80 solution was added and then secondary cultured. After hyaluronic acid was added and tertiary incubation, K 3 BO 3 was added thereto, and the reaction was stopped by heating in a boiling water. After centrifugation, N-acetylglucosamine (N-acetylglucosamine) produced by the decomposition of hyaluronic acid by hyaluronates was verified by colorimetric determination at 585 nm using DMAB (p-dimetylaminobenzaldehyde).
결과는 표 1에 나타내었다.The results are shown in Table 1.
표 1에 나타난 바와 같이, 본 발명의 오미자 추출물은 히알루로니데이즈의 활성을 현저히 억제함을 알 수 있다.As shown in Table 1, Schizandra extract of the present invention can be seen that significantly inhibit the activity of hyaluronidase.
실험예 2Experimental Example 2 : 오미자 추출물이 관절연골세포(C28/I2 cell) 증식 및 세포외기질 합성에 미치는 영향: Effect of Schizandra chinensis Extract on the Growth of Articular Chondrocytes (C28 / I2 Cells) and Extracellular Matrix Synthesis
본 발명의 오미자 추출물의 Human costal 연골세포에 대한 히알루로니데이즈 효소 저해 활성과 연골세포의 세포외기질 합성에 미치는 영향을 알아보기 위하여, 연골의 특이적인 세포외기질인 콜라겐 타입 Ⅱ의 발현양상을 RT-PCR을 통해 확인하였다.In order to investigate the effects of the hyaluronatease enzyme inhibitory activity and the extracellular matrix synthesis of chondrocytes on the human costal chondrocytes of Schizandra chinensis extract, the expression pattern of collagen type II, which is a specific extracellular matrix of cartilage, was determined by RT. -Confirmed by PCR.
Human costal 연골세포가 배양된 접시에 각각 1) 대조군(연골세포), 2) 히알루로니데이즈 처리군, 3) 오미자 추출물과 히알루로니데이즈 처리군으로, 처리한 후 24~72 시간 관찰하였다.Human costal chondrocytes were cultured in 1) control group (chondrocytes), 2) hyaluronidase treated group, 3) Schizandra extract and hyaluronidase treated groups, and observed for 24 ~ 72 hours.
단층 배양된 연골세포를 떼어낸 후 총 RNA는 Trizol Reagent(RNA extraction Kit, GIBCOBRL)를 이용하여 분리하였다. 각각의 군에 대하여 동량의 RNA를 AMV 역전사효소(BMS)를 이용하여 complementary DNA(cDNA)를 만든 뒤, 이를 템플레이트 (template)로 하여 콜라겐 타입 Ⅱ와 GAPDH에 대한 각각의 프라이머를 제작하여 PCR로 증폭시킨 후 아가로즈겔에 전기영동하여 변화를 확인하였다.After removing monolayer cultured chondrocytes, total RNA was isolated using Trizol Reagent (RNA extraction Kit, GIBCOBRL). Complementary DNA (cDNA) was prepared using AMV reverse transcriptase (BMS) for the same amount of RNA for each group, which was then amplified by PCR using primers for collagen type II and GAPDH. After the change was confirmed by electrophoresis on the agarose gel.
결과는 도2에 나타내었다.The results are shown in FIG.
도 2에 나타난 바와 같이, 본 발명의 오미자 추출물을 처리하면 히알루로니데이즈 단독 처리군 보다 콜라게 발현이 증대된 것을 알 수 있으며, 이는 오미자 추출물이 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 다시 억제하는 것을 알 수 있다.As shown in Figure 2, the treatment of the Schizandra chinensis extract of the present invention can be seen that the collagen expression is increased than the hyaluronidase alone treatment group, which is that Schizandra extract inhibits the synthesis of extracellular matrix of chondrocytes. It can be seen that it suppresses again.
따라서, 본 발명의 오미자 추출물이 히아루로니데이즈의 활성을 억제함을 알 수 있다.Therefore, it can be seen that the Schizandra chinensis extract of the present invention inhibits the activity of hyaluronides.
본 발명의 오미자 추출물을 유효성분으로 함유하는 조성물은, 골관절염 환자에게서 일반적으로 발생되는 관절내의 히알루로니데이즈에 의한 히알루론산 분해를 탁월하게 억제하고 히알루로니데이즈가 연골세포의 세포외기질 합성을 억제하는 것을 억제함으로서, 관절염의 예방 및 치료를 위한 의약 및 건강식품에 유용하게 사용될 수 있다.The composition containing the Schizandra chinensis extract of the present invention as an active ingredient is excellent in inhibiting hyaluronic acid degradation by hyaluronic acid in the joints commonly occurring in osteoarthritis patients, and hyaluronicase inhibits the extracellular matrix synthesis of chondrocytes. It can be usefully used in medicine and health foods for the prevention and treatment of arthritis by suppressing that.
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030052875 | 2003-07-30 | ||
KR20030052875 | 2003-07-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050115865A Division KR100597235B1 (en) | 2003-07-30 | 2005-11-30 | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050014615A true KR20050014615A (en) | 2005-02-07 |
KR100542876B1 KR100542876B1 (en) | 2006-01-20 |
Family
ID=37104931
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030061934A KR100542876B1 (en) | 2003-07-30 | 2003-09-04 | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis |
KR1020050115865A KR100597235B1 (en) | 2003-07-30 | 2005-11-30 | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050115865A KR100597235B1 (en) | 2003-07-30 | 2005-11-30 | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR100542876B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011019153A2 (en) * | 2009-08-12 | 2011-02-17 | (주) 와이디생명과학 | Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient |
KR20180044772A (en) * | 2016-10-24 | 2018-05-03 | 주식회사 바이오포트코리아 | Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof |
KR20190036903A (en) | 2017-09-28 | 2019-04-05 | (주)휴럼 | Litsenolide used as an active ingredient for prevention and treatment of inflammation and osteoarthritis, and A composition comprising the same as an active ingredient |
WO2019177327A1 (en) * | 2018-03-12 | 2019-09-19 | 한국 한의학 연구원 | Composition comprising schisandra chinensis extract as effective ingredient for prevention, alleviation, or treatment of arthritis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100930910B1 (en) | 2007-10-10 | 2009-12-10 | 문경시 | Beverage containing fresh Schisandra chinensis liquid and its manufacturing method |
WO2012045400A1 (en) * | 2010-10-05 | 2012-04-12 | Cognis Ip Management Gmbh | An extract of the fruit of the plant schisandra chinensis |
KR20150115414A (en) * | 2014-04-04 | 2015-10-14 | 한국생명공학연구원 | The pharmaceutical compositions for prevention or treatment of inflammatory diseases or promotion of wound healing containing ethylacetate fraction of Schizandra chinensis Baillon |
KR20240131530A (en) | 2023-02-23 | 2024-09-02 | 동의과학대학교산학협력단 | A health drink composition containing herbal extracts with excellent muscle and bone strengthening effects as active ingredients |
-
2003
- 2003-09-04 KR KR1020030061934A patent/KR100542876B1/en active IP Right Grant
-
2005
- 2005-11-30 KR KR1020050115865A patent/KR100597235B1/en active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011019153A2 (en) * | 2009-08-12 | 2011-02-17 | (주) 와이디생명과학 | Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient |
WO2011019153A3 (en) * | 2009-08-12 | 2011-03-31 | (주) 와이디생명과학 | Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient |
KR20180044772A (en) * | 2016-10-24 | 2018-05-03 | 주식회사 바이오포트코리아 | Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof |
KR20190036903A (en) | 2017-09-28 | 2019-04-05 | (주)휴럼 | Litsenolide used as an active ingredient for prevention and treatment of inflammation and osteoarthritis, and A composition comprising the same as an active ingredient |
WO2019177327A1 (en) * | 2018-03-12 | 2019-09-19 | 한국 한의학 연구원 | Composition comprising schisandra chinensis extract as effective ingredient for prevention, alleviation, or treatment of arthritis |
Also Published As
Publication number | Publication date |
---|---|
KR100597235B1 (en) | 2006-07-06 |
KR20060001877A (en) | 2006-01-06 |
KR100542876B1 (en) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR100589050B1 (en) | Composition comprising Astragali Radix extract and isoflavonoid compound isolated from the same as an effective component for preventing and treating arthritis | |
KR100626358B1 (en) | Herbal mixture extract of Notoginseng Radix, Rehmanniae Radix Preparata and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of arthritis | |
JP4496127B2 (en) | Herbal extract mixture and preventive or therapeutic agent for osteoporosis | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR20050114929A (en) | Composition for treating and preventing constipation | |
KR100874778B1 (en) | Composition for the prevention and treatment of menopausal diseases comprising fermented Cheonggukjang extract | |
KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
KR100680628B1 (en) | A herbal mixture extract of Rehmanniae Radix Preparata and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis | |
KR101023487B1 (en) | Arthritis prevention or treatment composition comprising a mixed herbal extract of Schisandra chinensis, golden and thawed skin as an active ingredient | |
KR20200014566A (en) | A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume | |
KR20100009151A (en) | Composition containing mixture extract of saururus chinesis and scutellaria baicalensis for prevention or treatment of osteoporosis | |
KR100656571B1 (en) | Composition for preventation and treatment of degenerative arthritis | |
KR20220000185A (en) | A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract | |
KR20110051545A (en) | Composition for preventing or treating gout comprising mulberry fermentation extract | |
KR100538983B1 (en) | Pharmaceutical composition comprising the crude drug extract for improving liver function | |
KR102545762B1 (en) | Composition for preventing or treating osteoarthritis comprising Gloiopeltis tenax estract | |
KR102448274B1 (en) | Composition for preventing, ameliorating or treating bone disease comprising crude polysaccharide fraction of Psoralea corylifolia extract as effective component | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
KR20230161338A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Spiraea prunifolia var. simpliciflora extract as effective component | |
KR20230161341A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Lysimachia mauritiana extract as effective component | |
KR20230161337A (en) | Composition for prevention, improvement or treatment of arthritis comprising Lysimachia japonica extract as effective component | |
KR20230161339A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130103 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131217 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141204 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161220 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171213 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 15 |